Ishara Investments
Ishara Investments reported 40 stocks worth $120M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are TVTX (7.1%), CYTK (7.1%) and BBIO (5.5%). Compared with Q2 2026, the fund opened new positions in TARS, PTCT and ARQT, added to TVTX, CYTK and BBIO, trimmed ACAD, PRAX and XERS and sold out of AGIO, INSM and TNXP.
Latest filing: what Ishara Investments did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() TVTX Travere Therapeutics Inc | $8.5M | 7.1% | 145K | +63K (+77%) | 3 of 4 | |
| 2 | ![]() CYTK Cytokinetics Inc | $8.4M | 7.1% | 128K | +95K (+290%) | 2 of 4 | |
| 3 | ![]() BBIO Bridgebio Pharma Inc | $6.6M | 5.5% | 100K | +43K (+74%) | 3 of 4 | |
| 4 | ![]() ACAD Acadia Pharmaceuticals Inc | $6.4M | 5.4% | 320K | −90K (−22%) | 4 of 4 | |
| 5 | ![]() TARS Tarsus Pharmaceuticals Inc | $5.5M | 4.6% | 70K | New position | 2 of 4 | |
| 6 | ![]() PTCT Ptc Therapeutics Inc | $5.2M | 4.3% | 80K | New position | 3 of 4 | |
| 7 | ![]() PRAX Praxis Precision Medicines I | $5M | 4.1% | 17K | −5,550 (−25%) | 4 of 4 | |
| 8 | ![]() VERA Vera Therapeutics Inc | $4.8M | 4.0% | 150K | +140K (+1363%) | 3 of 4 | |
| 9 | ![]() ARQT Arcutis Biotherapeutics Inc | $4.8M | 4.0% | 180K | New position | 2 of 4 | |
| 10 | ![]() ANNX Annexon Inc | $4.7M | 4.0% | 1.1M | +300K (+37%) | 4 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() AGIO Agios Pharmaceuticals Inc | $6.1M | 164K |
![]() INSM Insmed Inc | $5.5M | 51K |
CRINETICS PHARMACEUTICALS IN | $5.4M | 144K |
![]() TNXP Tonix Pharmaceuticals Hldg C | $4.3M | 338K |
![]() KURA Kura Oncology Inc | $3M | 277K |
🔒 Free account: see all 17.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() RARE Ultragenyx Pharmaceutical in | Put | $1.5M | 1,000 | +1,000 |
Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Ishara Investments 13F FAQ
What does Ishara Investments own?
Ishara Investments reported 40 stocks worth $120M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are TVTX (7.1%), CYTK (7.1%) and BBIO (5.5%). The table above lists every position in the filing (the top 10 without an account).
What did Ishara Investments buy and sell in Q3 2026?
Compared with Q2 2026: 16 new positions, 12 added to, 12 trimmed and 17 sold out. New positions include TARS, PTCT and ARQT. It sold all of AGIO, INSM and TNXP.
When will Ishara Investments file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Ishara Investments's portfolio worth?
The Q3 2026 filing reports $120M in US stocks ($121M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.





















